Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children With Down Syndrome

NCT00570128 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00570128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00570128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children With Down Syndrome
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2007
Completion date
September 5, 2008
Enrollment
129 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome